CSF1R and glioblastoma: Combinatorial therapies. Considering TAM’s immunosuppressive function and despite failed efficacy of CSF1R inhibitor as a single agent in unselected adult recurrent GBM patients [104], combinatorial therapies targeting CSF1R with novel emerging immunotherapies have been initiated to determine whether there are synergistic effects.